BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gleevec: Interim Phase III data

Researchers at Institut Gustave Roussy and colleagues reported interim data from an open-label, French Phase III trial in 50 evaluable patients with non-progressive GIST after 3 years of treatment with Gleevec showing that...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >